GI Hepatobiliary

Hepatocellular Carcinoma

Localized

No Prior Therapy

Prior Therapy

1st Line

2nd Line or more

1st Line

No Prior Therapy

Prior Therapy

1st Line

2nd Line or more

No Trials Currently Available

Cholangiocarcinoma

IRB# 20744
Pembrolizumab + Lenvatinib + TACE (Transarterial Chemoembolization) vs Placebo + TACE in Intermediate Stage HCC

IRB# 23365
A Phase II Study to Evaluate the Efficacy and Safety of Y-90, Atezolizumab and Cabozantinib Among Patients with unresectable and locally-advanced HCC

IRB# 20929
Phase II study of TSR-022 (COBOLIMAB) in combination with TSR-042 (DOSTARIMAB) for the treatment of advanced hepatocellular carcinoma

IRB# 20357
[NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

IRB# 16033
Phase II study of induction systemic mFOLIRINOX followed by hepatic arterial infusion of Fluorouridine and Dexamethasone given concurrently with systemic mFOLIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma

IRB# 24855
A Randomized Phase II Study of Intrabucally Administered Electromagnetic Fields versus Placebo as Second or Third -line Therapy for Patients with Child-Pugh A or B Advanced Hepatocellular Carcinoma as Second or Third -line Therapy for Patients with Child-Pugh A or B Advanced HCC

CROSS-DISEASE TRIALS:

IRB# TBD
EAY131 (MATCH)

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
IRB# 23005
EA2197, Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial